Nuo Therapeutics CEO buys 7,984 shares at $1.089

Nuo Therapeutics, Inc. (AURX) reported that its CEO/CFO, Jorden David Emerson, acquired shares of the company’s common stock in two Form 4-reported transactions.

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. (AURX) reported that its CEO/CFO, Jorden David Emerson, acquired shares of the company’s common stock in two Form 4-reported transactions. On 2026-08-28, he acquired 7,984 shares at a weighted average price of $1.089 per share, executed in multiple trades between $1.08 and $1.10. On 2026-08-27, he acquired an additional 789 shares at $1.07 per share. These are reported as grant/award or other acquisitions, and post-transaction share holdings are not stated in this filing.

Insider Trade Summary

Grant/Award: 8,773 shares

Grant/Award 2 txns

Insider JORDEN DAVID EMERSON

Role CEO/CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	7,984	$1.089	$9K
Grant/Award	Common Stock	789	$1.07	$844.23

Holdings After Transaction: Common Stock — 2,070,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

Key Figures

Shares acquired on 2026-08-28: 7,984 shares of Common Stock Weighted average price on 2026-08-28: $1.089 per share Price range on 2026-08-28 trades: $1.08 to $1.10 per share +3 more

6 metrics

Shares acquired on 2026-08-28 7,984 shares of Common Stock Grant, award, or other acquisition on 2026-08-28

Weighted average price on 2026-08-28 $1.089 per share Multiple transactions at prices ranging from $1.08 to $1.10, inclusive

Price range on 2026-08-28 trades $1.08 to $1.10 per share Range of prices for the 7,984-share acquisition

Shares acquired on 2026-08-27 789 shares of Common Stock Grant, award, or other acquisition on 2026-08-27

Price on 2026-08-27 $1.07 per share Reported transaction price for the 789-share acquisition

Number of acquisition transactions 2 transactions Both reported with transaction code A (grant, award, or other acquisition)

Key Terms

weighted average price, grant, award, or other acquisition, Common Stock

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AURX report for CEO/CFO Jorden David Emerson?

AURX reported that CEO/CFO Jorden David Emerson acquired common stock in two transactions: 7,984 shares on 2026-08-28 and 789 shares on 2026-08-27, both reported as grant, award, or other acquisitions of Nuo Therapeutics common stock.

At what prices did the AURX insider share acquisitions occur?

On 2026-08-28, Emerson’s acquisition had a weighted average price of $1.089 per share, with trades between $1.08 and $1.10. On 2026-08-27, he acquired shares at $1.07 per share, according to the Form 4 data and related footnote.

How many AURX shares did the CEO/CFO acquire on 2026-08-28?

On 2026-08-28, CEO/CFO Jorden David Emerson acquired 7,984 shares of Nuo Therapeutics, Inc. common stock at a weighted average price of $1.089 per share, with individual transactions executed in a price range from $1.08 to $1.10 per share.

How many AURX shares did the CEO/CFO acquire on 2026-08-27?

On 2026-08-27, CEO/CFO Jorden David Emerson acquired 789 shares of Nuo Therapeutics, Inc. common stock at a reported price of $1.07 per share, classified on the Form 4 as a grant, award, or other acquisition of common stock.

Does the AURX Form 4 indicate these insider trades were under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is unchecked (aff_10b5_one is false), and the footnote does not state that the transactions were made pursuant to a Rule 10b5-1 trading plan or other pre-arranged trading arrangement.

What does the weighted average price disclosure mean in the AURX Form 4?

For the 7,984-share acquisition on 2026-08-28, the Form 4 notes a weighted average price of $1.089 per share. The footnote explains the shares were purchased in multiple transactions at prices between $1.08 and $1.10, and full trade details are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 09:47 PM EDT Accepted by SEC EDGAR 08/28/2026 - 09:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JORDEN DAVID EMERSON

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO/CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2026		A		789	A	$1.07	2,062,016	D
Common Stock	08/28/2026		A		7,984	A	$1.089(1)	2,070,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

	/s/ David Jorden	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)